BOTOX - UROLOGY
Drug
Allergan Inc.
Total Payments
$1.9M
Transactions
928
Doctors
360
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $1.9M | 926 | 358 |
| 2017 | $30.82 | 2 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.9M | 400 | 98.2% |
| Food and Beverage | $19,731 | 523 | 1.0% |
| Consulting Fee | $15,350 | 5 | 0.8% |
Payments by Type
Research
$1.9M
400 transactions
General
$35,081
528 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE AN ENHANCED INJECTION PARADIGM FOR ONABOTULINUMTOXINA BOTOX IN THE TREATMENT OF OVERACTIVE BLADDER IN PATIENTS WITH URINARY INCONTINENCE | Allergan Inc. | $917,008 | 0 |
| A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Single Treatment, 2-Stage, Dose finding Study Evaluating the Efficacy and Safety of Botox Intravesical Installation in Participants with Overactive Bladder and Urinary Incontinence. | Allergan Inc. | $856,509 | 0 |
| DETERMINE VE CUTOFF RATIOS THAT PREDICT POST-PROCEDURE URINARY RETENTION REQUIRING CATHETERIZATION, AFTER TREATMENT WITH THERAPEUTIC DOSES OF BOTOX | Allergan Inc. | $39,693 | 0 |
| Prevalence of Comorbid Spasticity and Urinary Incontinence in Residents of a Long Term Care Facility | Allergan Inc. | $28,664 | 0 |
| The Impact of Injection Location on the Efficacy of Intravesicular Onabotulinumtoxin A in Interstitial Cystitis | Allergan Inc. | $28,225 | 0 |
| Qualitative Research to Evaluate the Symptoms and Impact of Overactive Bladder OAB | Allergan Inc. | $22,426 | 0 |
| A Double-blind Randomized Study to Compare Onobotuliumtoxin A versus Kenalog for Intravaginal Trigger Point Injections in the Treatment of Chronic Pelvic Pain | Allergan Inc. | $13,109 | 0 |
| Botulinum toxin Type A versus saline trigger point infections for myofascial pelvic pain | Allergan Inc. | $7,790 | 0 |
Top Doctors Receiving Payments for BOTOX - UROLOGY — Page 4
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Dermatology | Manhattan, KS | $108.44 | 1 |
| , M.D | Urology | Bronx, NY | $108.04 | 7 |
| , M.D | Urology | Las Vegas, NV | $105.74 | 1 |
| , M.D | Urology | Niles, IL | $105.43 | 1 |
| , M.D | Gynecology | Overland Park, KS | $102.08 | 1 |
| , MD | Urology | Wheaton, IL | $95.52 | 2 |
| , M.D | Specialist | Wheaton, IL | $95.52 | 2 |
| , M.D | Urology | Yonkers, NY | $93.78 | 6 |
| , MD | Urology | Las Vegas, NV | $92.67 | 1 |
| , M.D | Urology | Bronx, NY | $92.39 | 6 |
| , M.D | Specialist | White Plains, NY | $92.18 | 4 |
| , M.D | Urology | Bronx, NY | $91.68 | 6 |
| , MD | Urology | Brooklyn, NY | $90.48 | 5 |
| , M.D | Urology | San Francisco, CA | $90.25 | 1 |
| , MD | Urology | Dallas, TX | $88.83 | 1 |
| , MD | Urogynecology and Reconstructive Pelvic Surgery | Seattle, WA | $88.83 | 1 |
| , M.D | Urology | Burlington, MA | $88.83 | 1 |
| , MD | Urology | Cleveland, OH | $83.67 | 1 |
| , MD | Urology | New York, NY | $79.98 | 6 |
| , M.D | Urology | Wheaton, IL | $74.47 | 1 |
| , MD | Urology | White Plains, NY | $65.79 | 3 |
| , D.O | Urology | Iowa City, IA | $64.38 | 4 |
| , M.D | Urology | Fresno, CA | $63.16 | 3 |
| , M.D | Urology | Lake Barrington, IL | $63.14 | 3 |
| , MD | Urology | White Plains, NY | $63.11 | 3 |
Ad
Manufacturing Companies
- Allergan Inc. $1.9M
Product Information
- Type Drug
- Total Payments $1.9M
- Total Doctors 360
- Transactions 928
About BOTOX - UROLOGY
BOTOX - UROLOGY is a drug associated with $1.9M in payments to 360 healthcare providers, recorded across 928 transactions in the CMS Open Payments database. The primary manufacturer is Allergan Inc..
Payment data is available from 2017 to 2018. In 2018, $1.9M was paid across 926 transactions to 358 doctors.
The most common payment nature for BOTOX - UROLOGY is "Unspecified" ($1.9M, 98.2% of total).
BOTOX - UROLOGY is associated with 8 research studies, including "A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE AN ENHANCED INJECTION PARADIGM FOR ONABOTULINUMTOXINA BOTOX IN THE TREATMENT OF OVERACTIVE BLADDER IN PATIENTS WITH URINARY INCONTINENCE" ($917,008).